<p>股息增長股票可以是任何投資組合的理想長期選擇。這是因為它們不僅提供良好的分紅，而且隨着時間的推移可能會升值，從而幫助抵消通貨膨脹的負面影響。在最佳情況下，經過通貨膨脹調整後的收入最終會隨着時間的推移而增加。</p>
<p>目前有許多值得考慮的優質股息股票，因為它們的估值適中。特別是有三隻股票的收益率較高，分紅增長，並且看起來便宜。它們是 <strong>埃克森美孚</strong>(XOM 0.83%)、<strong>威瑞森</strong>(VZ -0.59%) 和 <strong>艾伯維</strong>(ABBV 0.12%)。</p>
<p>以下是您可能想要考慮今天購買這三隻便宜的股息增長股票的原因。</p>
<p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MjAwODYvYS1jb3VwbGUtc2hha2luZy1oYW5kcy13aXRoLWFuLWFkdmlzb3IuanBnJnc9NzAw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MjAwODYvYS1jb3VwbGUtc2hha2luZy1oYW5kcy13aXRoLWFuLWFkdmlzb3IuanBnJnc9NzAw"/></p>
<p>圖片來源：Getty Images。</p>
<h2>1. 埃克森美孚</h2>
<p>石油和天然氣巨頭埃克森美孚已經連續 42 年增加其年度股息。這在考慮到能源市場固有的波動性以及這對石油和天然氣生產商的收入和利潤的影響時，實在令人印象深刻。</p>
<p>目前，該股票的收益率為 3.76%，高於 <strong>標準普爾 500</strong> 的平均收益率 1.3%，也高於其三年平均收益率 3.4%。這也是一隻相對便宜的股票，因為埃克森美孚的市盈率不到 14 倍。</p>
<p>多年來，由於收購，該業務規模不斷擴大，這使其變得更加高效和盈利。去年，它完成了對先鋒自然資源公司的收購，這一舉措使其在二疊紀盆地的生產能力增加了一倍多。</p>
<p>無論是從股息收入還是長期穩定性來看，埃克森美孚都是一隻值得購買和持有的優秀股票。</p>
<h2>2. 威瑞森</h2>
<p>該名單中收益率最高的股票是威瑞森。它的收益率為 6.2%，略高於過去五年的平均 5.8%。這一高收益率的一個主要原因是該股票表現不佳，在過去五年中下跌超過 22%。高利率、缺乏增長以及資本密集型業務使得該股票對投資者看起來相當不具吸引力。</p>
<p>但如果您的優先考慮是穩定的股息，那麼考慮到其適中的估值，這可以是一隻很好的購買股票。該電信股票的市盈率不到 11 倍。儘管其增長前景可能並不理想，但也並非糟糕。公司仍預計今年核心無線服務業務的增長在 2% 到 2.8% 之間。預計自由現金流至少為 175 億美元，遠高於其每年支付的 110 億美元股息，因此其分紅仍然看起來安全。</p>
<p>威瑞森已經連續 18 年增加其股息，對於收入投資者來説，這可以是一隻優秀的持有股票，因為其適中的估值為投資者提供了良好的安全邊際。</p>
<h2>3. 艾伯維</h2>
<p>該名單的最後一項是醫療公司艾伯維。追溯到它作為 <strong>雅培</strong> 的一部分（2013 年分拆），該股票在技術上被歸類為股息之王，其年度增長的連續記錄超過 50 年。艾伯維可以為投資者提供兩全其美的選擇，因為它是一家不斷增長的製藥公司，並且提供吸引人的股息，目前的收益率為 3.5%。</p>
<p>該股票看起來較貴，市盈率約為 80 倍，但其數字受到收購相關費用的影響，在第四季度的業績中拖累了其利潤，導致其淨利潤為負。這仍然影響着其市盈率。但根據分析師的預期，該製藥公司的股票僅以 15 倍的估計未來利潤進行交易。</p>
<p>艾伯維是一家頂尖的醫療公司，擁有廣泛的產品組合，涵蓋免疫學、腫瘤學、神經科學，甚至美容（它擁有 Botox）。對於增長和股息投資者來説，這可以是一隻值得現在購買的優質股票。</p>

埃克森美孚

艾伯維

威瑞森

<p>本文強調了三隻值得考慮的股息增長股票：埃克森美孚、威瑞森通訊和艾伯維。埃克森美孚的股息收益率為 3.76%，並且有 42 年的股息增長曆史，當前交易價格不到 14 倍的收益。威瑞森的股息收益率為 6.2%，儘管近期面臨挑戰，但估值仍然適中，低於 11 倍的收益。艾伯維是一家股息之王，擁有超過 50 年的增長曆史，股息收益率為 3.5%，但由於近期支出，其收益倍數較高。這些股票被推薦用於長期收入和增長潛力</p>

<p>Dividend growth stocks can be ideal long-term options for any investment portfolio. That's because they not only offer a good payout, but they may also rise over time, helping offset the negative effects of inflation. In a best-case scenario, your inflation-adjusted income ends up rising over time as a result.</p>
<div class="lb-trans"><p>股息增長股票可以是任何投資組合的理想長期選擇。這是因為它們不僅提供良好的分紅，而且隨着時間的推移可能會升值，從而幫助抵消通貨膨脹的負面影響。在最佳情況下，經過通貨膨脹調整後的收入最終會隨着時間的推移而增加。</p>
</div><p>There are many solid dividend stocks right now worth considering because they trade at modest valuations. Three stocks, in particular, have high yields, have grown their payouts, and look cheap. They are <strong>ExxonMobil</strong>(XOM 0.83%), <strong>Verizon Communications</strong>(VZ -0.59%), and <strong>AbbVie</strong>(ABBV 0.12%).</p>
<div class="lb-trans"><p>目前有許多值得考慮的優質股息股票，因為它們的估值適中。特別是有三隻股票的收益率較高，分紅增長，並且看起來便宜。它們是 <strong>埃克森美孚</strong>(XOM 0.83%)、<strong>威瑞森</strong>(VZ -0.59%) 和 <strong>艾伯維</strong>(ABBV 0.12%)。</p>
</div><p>Here's why you may want to consider buying these three cheap dividend growth stocks today.</p>
<div class="lb-trans"><p>以下是您可能想要考慮今天購買這三隻便宜的股息增長股票的原因。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MjAwODYvYS1jb3VwbGUtc2hha2luZy1oYW5kcy13aXRoLWFuLWFkdmlzb3IuanBnJnc9NzAw" alt="" original-src="https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F820086%2Fa-couple-shaking-hands-with-an-advisor.jpg&amp;op=resize&amp;w=700"/></p>
<p>Image source: Getty Images.</p>
<div class="lb-trans"><p>圖片來源：Getty Images。</p>
</div><h2>1. ExxonMobil</h2>
<div class="lb-trans"><h2>1. 埃克森美孚</h2>
</div><p>Oil and gas giant ExxonMobil has increased its annual dividend for a remarkable 42 straight years. That's impressive when you consider the volatility inherent in the energy market and how that can weigh on an oil and gas producer's top and bottom lines.</p>
<div class="lb-trans"><p>石油和天然氣巨頭埃克森美孚已經連續 42 年增加其年度股息。這在考慮到能源市場固有的波動性以及這對石油和天然氣生產商的收入和利潤的影響時，實在令人印象深刻。</p>
</div><p>Currently, the stock yields 3.76%, which is better than the <strong>S&amp;P 500</strong> average yield of 1.3% and better than its three-year average of 3.4%. It's also a fairly cheap stock to buy, as ExxonMobil trades at less than 14 times its trailing earnings.</p>
<div class="lb-trans"><p>目前，該股票的收益率為 3.76%，高於 <strong>標準普爾 500</strong> 的平均收益率 1.3%，也高於其三年平均收益率 3.4%。這也是一隻相對便宜的股票，因為埃克森美孚的市盈率不到 14 倍。</p>
</div><p>Over the years, the business has become bigger due to acquisitions, which have allowed it to become more efficient and profitable. Last year, it completed its acquisition of Pioneer Natural Resources, a move that more than doubled its production capacity in the Permian Basin.</p>
<div class="lb-trans"><p>多年來，由於收購，該業務規模不斷擴大，這使其變得更加高效和盈利。去年，它完成了對先鋒自然資源公司的收購，這一舉措使其在二疊紀盆地的生產能力增加了一倍多。</p>
</div><p>For both its dividend income and long-term stability, ExxonMobil can make for a great stock to buy and hold.</p>
<div class="lb-trans"><p>無論是從股息收入還是長期穩定性來看，埃克森美孚都是一隻值得購買和持有的優秀股票。</p>
</div><h2>2. Verizon Communications</h2>
<div class="lb-trans"><h2>2. 威瑞森</h2>
</div><p>The stock with the highest yield on this list is Verizon. It pays 6.2%, somewhat higher than the 5.8% it has averaged over the past five years. A big reason for that high yield is that the stock has struggled, falling more than 22% in the past five years. High interest rates, a lack of growth, and a capital-intensive business have all made the stock look fairly unappealing to investors.</p>
<div class="lb-trans"><p>該名單中收益率最高的股票是威瑞森。它的收益率為 6.2%，略高於過去五年的平均 5.8%。這一高收益率的一個主要原因是該股票表現不佳，在過去五年中下跌超過 22%。高利率、缺乏增長以及資本密集型業務使得該股票對投資者看起來相當不具吸引力。</p>
</div><p>But if your priority is a solid dividend, then this can be a great stock to buy, given its modest valuation. The telecom stock trades at less than 11 times its earnings. And while its growth prospects may not be fantastic, they aren't terrible, either. The company still anticipates between 2% and 2.8% growth in its core wireless service business this year. With estimated free cash flow of at least $17.5 billion, which is much more than the $11 billion it pays in dividends over the course of a full year, its payout still looks safe.</p>
<div class="lb-trans"><p>但如果您的優先考慮是穩定的股息，那麼考慮到其適中的估值，這可以是一隻很好的購買股票。該電信股票的市盈率不到 11 倍。儘管其增長前景可能並不理想，但也並非糟糕。公司仍預計今年核心無線服務業務的增長在 2% 到 2.8% 之間。預計自由現金流至少為 175 億美元，遠高於其每年支付的 110 億美元股息，因此其分紅仍然看起來安全。</p>
</div><p>Verizon has increased its dividend for 18 straight years, and for income investors, this can be an excellent stock to hang on to, as its modest valuation offers investors a good margin of safety.</p>
<div class="lb-trans"><p>威瑞森已經連續 18 年增加其股息，對於收入投資者來説，這可以是一隻優秀的持有股票，因為其適中的估值為投資者提供了良好的安全邊際。</p>
</div><h2>3. AbbVie</h2>
<div class="lb-trans"><h2>3. 艾伯維</h2>
</div><p>Rounding out this list is healthcare company AbbVie. Dating back to its time when it was part of <strong>Abbott Laboratories</strong>(it spun off in 2013), the stock is technically classified as a Dividend King, with its streak of annual increases going back 50-plus years. AbbVie can give investors the best of both worlds, as it's a growing pharma business, and it offers an attractive dividend, which currently yields 3.5%.</p>
<div class="lb-trans"><p>該名單的最後一項是醫療公司艾伯維。追溯到它作為 <strong>雅培</strong> 的一部分（2013 年分拆），該股票在技術上被歸類為股息之王，其年度增長的連續記錄超過 50 年。艾伯維可以為投資者提供兩全其美的選擇，因為它是一家不斷增長的製藥公司，並且提供吸引人的股息，目前的收益率為 3.5%。</p>
</div><p>The stock looks expensive, as it trades at an earnings multiple of around 80, but its numbers have been weighed down by acquisition-related expenses in its fourth-quarter results, which dragged its bottom line into the negative. And that's still weighing on its earnings multiple. But based on analyst expectations, the drugmaker's stock trades at just 15 times its estimated future profits.</p>
<div class="lb-trans"><p>該股票看起來較貴，市盈率約為 80 倍，但其數字受到收購相關費用的影響，在第四季度的業績中拖累了其利潤，導致其淨利潤為負。這仍然影響着其市盈率。但根據分析師的預期，該製藥公司的股票僅以 15 倍的估計未來利潤進行交易。</p>
</div><p>AbbVie is a top healthcare company with a vast portfolio of products in immunology, oncology, neuroscience, and even aesthetics (it owns Botox). For both growth and dividend investors, this can be a solid stock to buy right now.</p>
<div class="lb-trans"><p>艾伯維是一家頂尖的醫療公司，擁有廣泛的產品組合，涵蓋免疫學、腫瘤學、神經科學，甚至美容（它擁有 Botox）。對於增長和股息投資者來説，這可以是一隻值得現在購買的優質股票。</p>
</div>

3 Cheap Dividend Growth Stocks to Buy Right Now

- 分紅增長股票是長期投資組合的理想選擇，能抵消通脹影響。  
- 當前推薦的三隻股票為 ExxonMobil、Verizon 和 AbbVie，均具高收益和增長潛力。  
- ExxonMobil 連續 42 年增息，Verizon 股息高達 6.2%，AbbVie 具 50 年增息記錄。  

3 只價格低廉的股息增長股票值得立即買入